Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Blocking Bacterial Naphthohydroquinone Oxidation and ADP-Ribosylation Improves Activity of Rifamycins against Mycobacterium abscessus

6 Jul 2021

Abstract excerpt

like rifampicin, preventing it from achieving the nanomolar activity that it displays against M. tuberculosis. Based on the identified dual mechanism of intrinsic rifamycin resistance, we hypothesized that rifamycins more potent than rifabutin should contain the molecule's naphthoquinone core plus a modification that blocks ADP-ribosylation at its C-23. To test these predictions, we performed a blinded screen of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Infectious Diseases and Mycology
Share to Mycobacterium research and diagnosis
Share to Tuberculosis Research and Epidemiology

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34228543
DOI: 10.1128/aac.00978-21

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Blocking Bacterial Naphthohydroquinone Oxidation and ADP-Ribosylation Improves Activity of Rifamycins against Mycobacterium abscessusPMID 34228543Read ↗

C25-modified rifamycin derivatives with improved activity against Mycobacterium abscessusSemantic proximity Read ↗

Pharmacological validation of dihydrofolate reductase as a drug target in Mycobacterium abscessusSemantic proximity Read ↗

Rifamycin antibiotic resistance by ADP-ribosylation: Structure and diversity of Arr.Semantic proximity Read ↗

Rational Exploration of 2,4-Diaminopyrimidines as DHFR Inhibitors Active against Mycobacterium abscessus and Mycobacterium avium, Two Emerging Human PathogensSemantic proximity Read ↗

REBASTINIB, OLVEREMBATINIB, AND NAS-181 INHIBIT <i>MYCOBACTERIUM ABSCESSUS</i> BY DISRUPTING MYCOTHIOL HOMEOSTASISSemantic proximity Read ↗

Discovery of inhibitors for bacterial Arr enzymes ADP-ribosylating and inactivating rifamycin antibioticsSemantic proximity Read ↗

Pathogen Box screening for hit identification against Mycobacterium abscessusSemantic proximity Read ↗

Pipeline of anti‐Mycobacterium abscessussmall molecules: Repurposable drugs and promising novel chemical entitiesSemantic proximity Read ↗

Mycothione reductase as a potential target in the fight against Mycobacterium abscessus infectionsSemantic proximity Read ↗

Rifabutin Is Active against Mycobacterium abscessus ComplexSemantic proximity Read ↗

2-Carboxyquinoxalines kill mycobacterium tuberculosis through noncovalent inhibition of DprE1.Semantic proximity Read ↗

Discovery of pyrazolopyridones as a novel class of noncovalent DprE1 inhibitor with potent anti-mycobacterial activity.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.